Glucagon-like peptide-1 analog

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes.^[1]

One of their advantages (over insulin?) is that they have a lower risk of causing hypoglycemia.^{[citation needed]}

Licenced : exenatide (2005), liraglutide (2010)^[2]

[edit] References

Biguanides	Metformin^# • Buformin^‡ • Phenformin^‡

TZDs (PPAR)	Pioglitazone • Rivoglitazone^† • Rosiglitazone • Troglitazone^‡

Dual PPAR agonist	Aleglitazar^† • Muraglitazar^§ • Tesaglitazar^§

Sulfonylureas	1st generation: Acetohexamide • Carbutamide • Chlorpropamide • Metahexamide • Tolbutamide • Tolazamide 2nd generation: Glibenclamide (Glyburide)^# • Glibornuride • Glipizide • Gliquidone • Glisoxepide • Glyclopyramide • Glimepiride • Gliclazide

Meglitinides/"glinides"	Nateglinide • Repaglinide • Mitiglinide

GLP-1 analogs

Analogs/other insulins

fast-acting (Insulin lispro • Insulin aspart • Insulin glulisine) • short-acting (Regular insulin) • long-acting (Insulin glargine • Insulin detemir • NPH insulin) • ultra-long-acting (Insulin degludec^†) • inhalable Exubera^‡

Other

Alpha-glucosidase inhibitors	Acarbose • Miglitol • Voglibose

Amylin analog	Pramlintide

SGLT2 inhibitors	Canagliflozin^† • Dapagliflozin^† • Remogliflozin^§ • Sergliflozin^§

Other	Benfluorex^‡ • Tolrestat^‡